Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC cut its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 87.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 2,211 shares of the biotechnology company's stock after selling 15,789 shares during the period. AlphaCentric Advisors LLC's holdings in Sarepta Therapeutics were worth $269,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the business. Manchester Capital Management LLC grew its position in shares of Sarepta Therapeutics by 86.6% in the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB increased its stake in shares of Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Sunbelt Securities Inc. increased its stake in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 232 shares during the last quarter. Huntington National Bank lifted its holdings in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new stake in shares of Sarepta Therapeutics in the fourth quarter worth approximately $36,000. Hedge funds and other institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Stock Up 1.2 %

NASDAQ SRPT traded up $1.29 during mid-day trading on Thursday, reaching $108.41. 836,109 shares of the company's stock traded hands, compared to its average volume of 814,512. The company has a market cap of $10.36 billion, a price-to-earnings ratio of 86.73 and a beta of 0.75. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics, Inc. has a 1-year low of $101.15 and a 1-year high of $173.25. The company has a fifty day simple moving average of $117.88 and a 200-day simple moving average of $123.85.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on SRPT shares. StockNews.com lowered shares of Sarepta Therapeutics from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. HC Wainwright reaffirmed a "sell" rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 13th. Guggenheim boosted their price target on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Cantor Fitzgerald upgraded Sarepta Therapeutics from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Piper Sandler reduced their price objective on Sarepta Therapeutics from $200.00 to $182.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. One analyst has rated the stock with a sell rating, three have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $176.77.

Insider Activity at Sarepta Therapeutics

In related news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the completion of the sale, the director now owns 22,840 shares of the company's stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. This trade represents a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.